People with eczema have less ceramide in their skin, that much has been known for decades. But does the ceramide drop cause the eczema, or does the eczema cause the ceramide drop? A team at Japan's Utsunomiya University has finally cracked this chicken-or-egg question with the world's first direct proof: ceramide deficiency comes first, and everything else follows.

What Are Ceramides, and Why Should You Care?

Ceramides are a type of lipid (fat molecule) found in the outermost layer of your skin, called the stratum corneum. Think of them as the mortar between the bricks of a wall, they fill the spaces between skin cells, forming a barrier that keeps irritants, allergens, and bacteria out while locking moisture in.

Since the 1990s, scientists have known that people with atopic dermatitis (AD), commonly known as eczema, have significantly lower ceramide levels in their skin compared to healthy individuals. But whether this ceramide shortage was a cause or merely a symptom of the disease remained one of dermatology's most stubborn unanswered questions.

The Experiment That Settled the Debate

Professor Genji Imokawa and his research team at Utsunomiya University's Bioscience Education and Research Center devised an elegant experiment to answer this question once and for all.

They created transgenic mice (genetically modified mice) that overexpressed an enzyme called acid ceramidase (aCDase) in the upper layers of their skin. This enzyme breaks down ceramides, so by cranking up its activity, the researchers could artificially deplete ceramides in the skin while leaving everything else untouched. In essence, they created mice with a ceramide deficiency and nothing else, then watched what happened.

The results were striking. From an early age, these mice developed:

  • Severe dryness and flaking skin (scaling)
  • Dramatically weakened skin barrier function and moisture retention
  • A major reduction in stratum corneum ceramides
  • Overgrowth of nerve fibers in the epidermis (the nerves that transmit itch signals)
  • A decrease in Semaphorin 3A (Sema3a), a molecule that normally keeps nerve growth in check

The critical test came when researchers exposed the mice to dust mite allergens, a common trigger for eczema in humans. The ceramide-deficient mice mounted a massive allergic response: eosinophil infiltration (a type of white blood cell associated with allergic reactions), elevated IgE antibodies in the blood, and a sharp increase in Th2-related immune molecules such as Ccl17, Ccl22, and Il13. Normal mice exposed to the same allergens showed virtually no reaction.

Ending the "Outside-In" vs. "Inside-Out" Debate

This finding has major implications for a long-running scientific debate about what causes eczema in the first place.

One school of thought, the "inside-out" hypothesis, holds that internal immune dysfunction comes first, which then damages the skin. The opposing "outside-in" hypothesis argues that skin barrier defects come first, allowing external irritants to penetrate and trigger the immune overreaction.

By demonstrating a clear cascade, ceramide deficiency → barrier breakdown → nerve hypersensitivity → Th2-type allergic inflammation, this study provides powerful evidence for the "outside-in" model. The immune chaos isn't the starting point; it's the consequence of a skin that has lost its protective seal.

A Global Problem That Keeps Growing

Eczema is far from a niche condition. According to a 2023 systematic analysis in the British Journal of Dermatology, approximately 204 million people worldwide, about 2.6% of the global population, are affected by atopic dermatitis. That figure includes roughly 103 million children and 101 million adults.

The disease burden is rising across both developed and developing nations, with urbanization and environmental changes driving much of the increase. In the United States alone, about 15.6% of children are affected, with significantly higher rates among Black children compared to White children. A 2025 global survey spanning 20 countries found an overall adult AD prevalence of 9.6%, with the highest rates in Asia.

The condition goes far beyond itchy skin. Severe eczema disrupts sleep, impairs quality of life, and is strongly associated with asthma, allergic rhinitis, and mental health challenges including depression and anxiety.

New Treatment Strategies on the Horizon

The research team says their findings open the door to several promising therapeutic approaches:

Scientific backing for ceramide replenishment therapy: Ceramide-containing moisturizers have been available for years, but this study provides the clearest scientific explanation yet for why they work. This could accelerate the development of more effective ceramide-based formulations that target the root cause of the disease.

Acid ceramidase inhibitors: Since the enzyme acid ceramidase is responsible for breaking down ceramides, drugs that inhibit this enzyme could prevent ceramide loss at its source, a fundamentally different approach from simply applying ceramides topically.

Itch-targeted skincare and early prevention: The discovery that ceramide deficiency triggers nerve fiber overgrowth, which amplifies the maddening itch cycle, opens new avenues for skincare products specifically designed to prevent itch before it starts. Early intervention with ceramide-focused products could potentially prevent eczema from developing in at-risk infants.

The Researcher Behind the Breakthrough

Professor Genji Imokawa is a pioneering figure in ceramide science. After completing his graduate studies at Nagoya University, he spent years at Kao Corporation, where he contributed to the development of well-known Japanese skincare brands Bioré and Curél. He is credited with discovering ceramide's moisture-retention function in the skin and identifying the specific enzyme (sphingomyelin deacylase) responsible for ceramide reduction in atopic skin. He also designed synthetic pseudo-ceramides that have been widely adopted in skincare products for dry and eczema-prone skin.

The study was published online on March 25, 2026 in The Journal of Pathology, a leading international pathology journal.

In Japan, ceramide-based skincare products are widely available at drugstores and are a standard part of eczema management. This research validates what many Japanese consumers and dermatologists have long practiced. How about in your country, is ceramide a familiar ingredient in skincare? What treatments are commonly used for eczema? We'd love to hear about your experience and perspective.

References